Communicable & Non-Communicable Disease Control

India is experiencing an epidemiological transition characterized by a "dual burden of disease": while communicable vector-borne and infectious diseases (such as tuberculosis, malaria, dengue, and filariasis) continue to challenge community health services, non-communicable chronic lifestyle conditions (such as cardiovascular disease, diabetes, hypertension, and malignant neoplasms) are surging across both rural and urban populations. The professional nursing officer must possess comprehensive competence in diagnostic testing, pharmacological regimens, adverse effect monitoring, vector biology, and population screening protocols.

1. Tuberculosis Control & National Tuberculosis Elimination Program (NTEP)

Strategic Overview & Etiology

• Program Vision: Formerly designated the Revised National Tuberculosis Control Programme (RNTCP), the program was rebranded as the National Tuberculosis Elimination Program (NTEP) in 2020. India set its national "End TB" goal for 2025, five years ahead of the United Nations Sustainable Development Goal (SDG) 2030 target.
• Causative Organism: Mycobacterium tuberculosis (MTB), an obligate aerobic, non-spore-forming, slow-growing, rod-shaped acid-fast bacillus (AFB). Possesses a waxy, lipid-rich cell wall packed with mycolic acid, which resists conventional Gram staining and protects the organism from intracellular macrophage destruction.
• Transmission: Spread via airborne droplet nuclei ($1\text{ to }5\ \mu\text{m}$ in diameter) generated when a patient with open cavitary pulmonary tuberculosis coughs, sneezes, speaks, sings, or spits. Droplet nuclei remain suspended in ambient indoor air currents for hours.

Modern Diagnostic Modalities under NTEP

1. Sputum Smear Microscopy:
   • Performed using Ziehl-Neelsen (ZN) acid-fast staining or light-emitting diode fluorescent microscopy (LED-FM).
   • Microscopic Appearance: Acid-fast bacilli resist acid-alcohol decolorization and appear as bright red/pink slender, curved rods against a contrasting light blue methylene blue background.
   • Sample Collection: NTEP mandates the examination of two sputum specimens: one Spot specimen collected at initial clinical presentation, and one Early Morning specimen collected immediately upon waking on the second day.
2. Cartridge-Based Nucleic Acid Amplification Test (CBNAAT / GeneXpert MTB/RIF):
   • A fully automated, closed cartridge-based hemi-nested real-time PCR platform.
   • Produces definitive diagnostic results within 2 hours.
   • Dual Diagnostic Function: Simultaneously identifies the presence of Mycobacterium tuberculosis DNA and detects genetic mutations in the rpoB gene that confer resistance to Rifampicin (serving as a proxy marker for Multidrug-Resistant TB).
   • Designated by NTEP as the first-line diagnostic test for all presumptive TB cases (pediatric TB, extrapulmonary TB, HIV-associated TB, and smear-negative presumptive cases).
3. TrueNat:
   • An indigenous, battery-operated, chip-based portable micro-PCR diagnostic platform.
   • Validated for point-of-care decentralized use at Primary Health Centres and remote sub-district units.
4. Mantoux Tuberculin Skin Test (TST):
   • Technique: Intradermal injection of 0.1 mL containing 5 Tuberculin Units (TU) of Purified Protein Derivative (PPD) into the volar aspect of the left forearm using a tuberculin syringe. Produces an immediate 6–10 mm pale cutaneous wheal.
   • Reading & Interpretation: The transverse diameter of palpable induration (firm raised tissue), NOT erythema, is measured with a transparent ruler at 48 to 72 hours:
     • $\ge 10\text{ mm}$ induration: Considered Positive in immunocompetent individuals.
     • $\ge 5\text{ mm}$ induration: Considered Positive in HIV-positive individuals, severely malnourished children, organ transplant recipients, or patients receiving immunosuppressive corticosteroids.
   • Clinical Caveat: A positive Mantoux test indicates previous cell-mediated immunological sensitization to mycobacterial antigens; it cannot distinguish between active clinical tuberculosis disease, latent tuberculosis infection (LTBI), or previous BCG vaccination.

Treatment Protocols for Drug-Susceptible Tuberculosis

NTEP delivers chemotherapy using daily Fixed-Dose Combinations (FDCs) in weight-banded blister packs, replacing the older intermittent thrice-weekly DOTS strategy:

  DRUG-SUSCEPTIBLE TB REGIMEN (Total Duration: 6 Months)
  ┌────────────────────────────────────────┬────────────────────────────────────────┐
  │     INTENSIVE PHASE (IP) - 2 MONTHS    │   CONTINUATION PHASE (CP) - 4 MONTHS   │
  │                (2 HRZE)                │                (4 HRE)                 │
  │ 8 Weeks / 56 Daily Doses:              │ 16 Weeks / 112 Daily Doses:            │
  │   • Isoniazid (H)                      │   • Isoniazid (H)                      │
  │   • Rifampicin (R)                     │   • Rifampicin (R)                     │
  │   • Pyrazinamide (Z)                   │   • Ethambutol (E)                     │
  │   • Ethambutol (E)                     │                                        │
  └────────────────────────────────────────┴────────────────────────────────────────┘

• Intensive Phase (IP, 2 Months / 56 Daily Doses): 4 drugs administered daily: Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E). Rapidly eliminates actively metabolizing bacilli, aborts infectious transmission, and prevents the emergence of drug resistance.
• Continuation Phase (CP, 4 Months / 112 Daily Doses): 3 drugs administered daily: Isoniazid (H) + Rifampicin (R) + Ethambutol (E). Eliminates persisting and slowly replicating dormant bacilli to achieve permanent biological cure and prevent relapse.

First-Line Anti-TB Drugs: Adverse Effects & Nursing Implications

1. Isoniazid (INH / H):
   • Bactericidal: Inhibits the synthesis of mycolic acids in the bacterial cell wall.
   • Adverse Effect: Peripheral Neuropathy: Isoniazid competes with pyridoxal phosphate, accelerating renal excretion of Vitamin B6 (Pyridoxine). Manifests as distal, symmetrical "glove-and-stocking" paresthesias, numbness, and burning pain.
   • Nursing Management: Prophylactically co-administer Pyridoxine 10 to 25 mg daily (increased to 50–100 mg daily if clinical neuropathy occurs). Monitor liver enzymes for drug-induced hepatitis.
2. Rifampicin (RIF / R):
   • Bactericidal: Inhibits DNA-dependent RNA polymerase, blocking bacterial RNA synthesis.
   • Adverse Effect: Harmless, striking red-orange discoloration of bodily secretions (urine, saliva, tears, sweat, and feces). Tears can permanently stain soft contact lenses.
   • Critical Nursing Precaution: Proactively reassure the patient that red-orange urine is a normal, harmless drug metabolite to prevent extreme panic and treatment non-compliance. Rifampicin is a potent inducer of hepatic Cytochrome P450 enzymes, significantly decreasing the efficacy of concurrent oral contraceptive pills (requiring non-hormonal barrier contraception), warfarin, oral hypoglycemics, and antiretrovirals. Monitor for hepatotoxicity.
3. Pyrazinamide (PZA / Z):
   • Bactericidal: Active in the acidic intracellular environment of necrotic caseous lesions and macrophage phagolysosomes.
   • Adverse Effect: Hyperuricemia & Arthralgia: Pyrazinamide inhibits renal tubular excretion of uric acid, producing intense polyarthralgias (especially in large weight-bearing joints) and precipitating acute gouty attacks. Has the highest hepatotoxic potential of all first-line anti-TB medications.
   • Nursing Management: Monitor serum uric acid levels; administer paracetamol or NSAIDs as ordered for arthralgias; encourage high fluid intake; perform baseline and serial liver function tests (LFTs).
4. Ethambutol (EMB / E):
   • Bacteriostatic: Inhibits arabinosyl transferase, impairing bacterial arabinogalactan cell wall synthesis. (Ethambutol is the only bacteriostatic agent among the first-line oral anti-TB medications).
   • Adverse Effect: Retrobulbar Optic Neuritis: Dose-dependent toxicity manifesting as decreased visual acuity, central scotomas, and loss of red-green color discrimination.
   • Nursing Management: Perform baseline and monthly visual acuity (Snellen chart) and color perception (Ishihara plates) examinations. Instruct patients to report visual blurring immediately. Used with caution (weight-band dosing) in young children who cannot reliably report color changes.
5. Streptomycin (SM / S):
   • Bactericidal: Aminoglycoside antibiotic that binds to the 30S ribosomal subunit to disrupt protein translation.
   • Adverse Effect: Irreversible Ototoxicity (damage to Cranial Nerve VIII, causing vestibular vertigo, tinnitus, and permanent sensorineural deafness) and Nephrotoxicity.
   • CRITICAL CONTRAINDICATION: STRICTLY CONTRAINDICATED IN PREGNANCY because it crosses the placenta, accumulates in fetal perilymph, and causes irreversible congenital fetal bilateral deafness.

Drug-Resistant Tuberculosis & Patient Support Schemes

• Multidrug-Resistant TB (MDR-TB): Disease caused by an MTB isolate demonstrating resistance to at least both Isoniazid and Rifampicin simultaneously.
• Extensively Drug-Resistant TB (XDR-TB): Form of MDR-TB with additional resistance to any fluoroquinolone (e.g., levofloxacin or moxifloxacin) and at least one Group A second-line drug (Bedaquiline or Linezolid).
• Modern Second-Line Therapeutics: Managed with newer oral regimens incorporating Bedaquiline (ATP synthase inhibitor), Delamanid (mycolic acid synthesis inhibitor), Linezolid, and Clofazimine.
• Nikshay Portal & Nikshay Poshan Yojana (NPY):
  • Nikshay Portal: A web-based digital surveillance and case management ecosystem for tracking notification, treatment adherence, and drug dispensing across both public and private healthcare sectors.
  • Nikshay Poshan Yojana: A Direct Benefit Transfer (DBT) scheme that provides financial assistance of ₹1,000 per month (doubled from ₹500 with effect from 1 November 2024) deposited directly into the bank account of every registered TB patient throughout the duration of treatment to support dietary nutrition.

2. Vector-Borne Disease Control (NVBDCP)

The National Vector Borne Disease Control Programme (NVBDCP) is the national umbrella program tasked with the prevention and control of six vector-borne diseases: Malaria, Dengue, Chikungunya, Japanese Encephalitis, Lymphatic Filariasis, and Kala-azar (Visceral Leishmaniasis).

1. Malaria

• Etiological Agents: Protozoan parasites of the genus Plasmodium. In India:
  • Plasmodium vivax: Responsible for 60% to 70% of total infections; characterized by relapses originating from dormant liver stages.
  • Plasmodium falciparum: Responsible for 30% to 40% of infections; causes severe, malignant, complicated malaria, blackwater fever, cerebral malaria, and mortality.
• Vector Biology: Female Anopheles mosquito (Anopheles culicifacies in rural agricultural zones; Anopheles stephensi in urban cisterns and overhead tanks). Nocturnal and crepuscular biters; breeds in clean, fresh water collections (irrigation channels, clear pools, river beds).
• The Classic Malarial Paroxysm (Cyclical every 48 hours in benign tertian malaria):
  1. Cold Stage (15 to 60 minutes): Intense uncontrollable shivering, teeth chattering, rigors, pale cold cyanotic skin; core body temperature climbs rapidly.
  2. Hot Stage (2 to 6 hours): Severe hyperpyrexia (temperature surges to 40°C–41°C / 104°F–106°F), excruciating throbbing headache, burning dry skin, intense thirst, nausea, delirium.
  3. Sweating Stage (2 to 4 hours): Profuse, drenching perspiration; rapid defervescence to normal or subnormal levels; physical exhaustion, weakness, and deep sleep.
• Severe Complicated Falciparum Malaria: Clinical emergencies include Cerebral Malaria (diffuse encephalopathy, unarousable coma, seizures), Blackwater Fever (massive intravascular hemolysis causing hemoglobinuria with dark port-wine/black urine and acute tubular necrosis), severe normocytic anemia, pulmonary edema, metabolic acidosis, and acute renal failure.
• Diagnostic Modalities:
  • Peripheral Blood Smear (Gold Standard):
    • Thick Smear: Dehemoglobinized, highly concentrated; used for sensitive detection of malaria parasites and parasite density estimation.
    • Thin Smear: Methanol-fixed; preserves red blood cell morphology for precise Plasmodium species identification.
  • Rapid Diagnostic Tests (RDT): Detects circulating antigens: Histidine-Rich Protein-2 (HRP-2) specific for P. falciparum, and Parasite Lactate Dehydrogenase (pLDH) for P. vivax and pan-species.
• Pharmacological Treatment Protocols:
  • P. vivax Malaria:
    • Chloroquine: Total dose of 25 mg/kg base spread over 3 days (10 mg/kg Day 1, 10 mg/kg Day 2, 5 mg/kg Day 3) to clear blood schizonts.
    • Primaquine: 0.25 mg/kg daily for 14 days to achieve radical cure by destroying dormant hepatic hypnozoites that cause secondary relapses.
    • CRITICAL SAFETY WARNING: Primaquine is strictly contraindicated in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the catastrophic risk of acute intravascular hemolytic anemia, and is contraindicated during pregnancy.
  • P. falciparum Malaria:
    • Artemisinin-based Combination Therapy (ACT):
      • In Northeast states: Artemether-Lumefantrine (AL) for 3 days.
      • In the rest of India: Artesunate + Sulfadoxine-Pyrimethamine (ACT-SP) for 3 days.
    • Single Dose Primaquine: Administered on Day 2 (0.75 mg/kg) as a potent gametocytocidal agent to prevent parasite transmission to mosquitoes.
  • Severe Malaria (Medical Emergency): Administer intravenous Artesunate at 2.4 mg/kg IV at 0, 12, and 24 hours, followed by once daily for a minimum of 24 hours until oral intake is established, completed by a full 3-day oral ACT course.

2. Dengue

• Etiology: Single-stranded RNA Flavivirus with 4 distinct antigenically related serotypes (DEN-1, DEN-2, DEN-3, DEN-4). Infection with one serotype confers permanent homotypic immunity, but secondary infection with a different serotype can trigger life-threatening Antibody-Dependent Enhancement (ADE).
• Vector Biology: Aedes aegypti (the "tiger mosquito" featuring white lyre markings on the scutum and white bands on legs). Strictly a day-biter (peak biting hours: 2 hours after sunrise and several hours before sunset). Breeds in clean, artificial, domestic and peri-domestic water collections (flower vases, discarded automobile tires, water cooler trays, uncovered plastic cisterns, coconut shells).
• Clinical Classifications:
  1. Classical Dengue Fever (Breakbone Fever): High fever, severe frontal headache, intense retro-orbital pain aggravated by eye motion, excruciating generalized arthralgias and myalgias, maculopapular rash, and a biphasic ("saddleback") fever curve.
  2. Dengue Hemorrhagic Fever (DHF): Must satisfy all four WHO criteria:
     • Acute sustained high fever (2 to 7 days)
     • Hemorrhagic tendencies, confirmed by a positive Tourniquet Test (inflating a blood pressure cuff midway between systolic and diastolic pressure for 5 minutes; positive if $\ge 20$ petechiae per 1 square inch / 2.5 cm² on the forearm)
     • Thrombocytopenia: Platelet count $< 100{,}000/\mu\text{L}$
     • Objective evidence of plasma leakage due to increased endothelial permeability: Hematocrit elevation $\ge 20\%$, pleural effusion, ascites, or hypoalbuminemia.
  3. Dengue Shock Syndrome (DSS): DHF progressing to circulatory collapse: rapid thready pulse, narrow pulse pressure ($\le 20\text{ mmHg}$, e.g., 90/75 mmHg), hypotension, cold clammy extremities, and metabolic acidosis.
• Nursing Care & Critical Contraindications:
  • Meticulous fluid resuscitation using isotonic crystalloids (0.9% Normal Saline or Ringer's Lactate) titrated to hematocrit and hourly urine output ($> 0.5\text{ to }1.0\text{ mL/kg/hr}$).
  • ABSOLUTE CONTRAINDICATION: Aspirin, Ibuprofen, Diclofenac, and all other NSAIDs are STRICTLY CONTRAINDICATED in dengue fever. NSAIDs inhibit platelet aggregation and erode gastric mucosa, triggering catastrophic gastrointestinal hemorrhage. Administer only Paracetamol for fever control.

3. Lymphatic Filariasis (Elephantiasis)

• Etiology: Nematode filarial worms. In India, Wuchereria bancrofti accounts for 99% of infections, with Brugia malayi responsible for remaining pockets.
• Vector: Culex quinquefasciatus mosquito. Breeds in stagnant, polluted, organically rich wastewater, sewage canals, soakage pits, and open gutters. Nocturnal biter.
• Pathophysiology & Presentation: Adult worms reside within human afferent lymphatic channels and lymph nodes, causing lymphatic endothelial inflammation, recurrent acute adenolymphangitis (ADL), progressive mechanical lymphatic obstruction, chronic lymphedema, hydrocele, and massive, disfiguring elephantiasis of the lower extremities and scrotum.
• Diagnostic Gold Standard: Demonstration of active microfilariae in a thick peripheral blood smear collected during the night between 10:00 PM and 2:00 AM, exploiting the parasite's nocturnal periodicity.
• National Elimination Strategy: Annual Mass Drug Administration (MDA) in endemic districts administering a single co-administered dose of Diethylcarbamazine (DEC, 6 mg/kg) PLUS Albendazole (400 mg), or modern Triple Drug Therapy (IDA: Ivermectin + DEC + Albendazole). Nursing care emphasizes meticulous daily foot hygiene with soap and water to prevent secondary bacterial infections that drive elephantiasis progression.

3. Non-Communicable Diseases (NCDs) & Population-Based Screening

National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD)

Formerly designated NPCDCS, the NP-NCD addresses the growing burden of chronic non-communicable conditions: Cardiovascular Diseases, Diabetes, Chronic Obstructive Pulmonary Disease, and Cancers.

Universal Population-Based Screening Protocols (Age $\ge 30$ Years)

Under Ayushman Bharat, female health workers (ANMs) and Community Health Officers (CHOs) at Ayushman Arogya Mandirs screen all individuals 30 years of age and older for five major conditions:

               POPULATION-BASED SCREENING AT HWCs (Age >= 30 Years)
   ┌───────────────────────┬───────────────────────┬───────────────────────┐
   │      HYPERTENSION     │        DIABETES       │    CANCER SCREENING   │
   │ Digital / Aneroid BP  │ Random Blood Glucose  │ • Oral: OVE Inspection│
   │ Cutoff: >= 140/90     │ Cutoff: >= 140 mg/dL  │ • Breast: CBE + BSE   │
   │ Lifestyle + Amlodipine│ Fasting test / Refer  │ • Cervical: VIA Test  │
   └───────────────────────┴───────────────────────┴───────────────────────┘

1. Hypertension Screening:
   • Screened using a calibrated digital or aneroid sphygmomanometer.
   • Cutoff Value: Systolic Blood Pressure $\ge 140\text{ mmHg}$ and/or Diastolic Blood Pressure $\ge 90\text{ mmHg}$ measured on two separate occasions.
   • Nursing Management: Dietary counseling to restrict sodium intake to $< 5\text{ g/day}$ (less than 1 level teaspoon of salt daily), smoking and alcohol cessation, daily moderate aerobic physical activity for 30 minutes, and initiation of first-line antihypertensive therapy (e.g., Amlodipine 5 mg, Telmisartan 40 mg).
2. Type 2 Diabetes Mellitus Screening:
   • Screened using a point-of-care capillary blood glucometer.
   • Screening Cutoff: Random Capillary Blood Glucose $\ge 140\text{ mg/dL}$ triggers confirmation via fasting venous plasma glucose (fasting plasma glucose $\ge 126\text{ mg/dL}$ or random plasma glucose $\ge 200\text{ mg/dL}$ confirms diabetes).
   • Nursing Management: Lifestyle intervention, diabetic foot care education, weight reduction, and referral to the PHC Medical Officer for Metformin initiation.
3. Oral Cancer Screening:
   • Oral Visual Examination (OVE): Systemic visual inspection and palpation of the oral mucosa, gingiva, buccal mucosa, hard palate, and tongue under good illumination using a wooden tongue depressor.
   • Clinical Red Flags: Leukoplakia (persistent, adherent white patch that cannot be wiped away with gauze), Erythroplakia (bright red velvety plaque possessing high malignant potential), oral submucous fibrosis (blanched marble mucosa with severe trismus), and chronic non-healing indurated ulcers lasting $> 2$ weeks. Prompt referral for biopsy.
4. Breast Cancer Screening:
   • Clinical Breast Examination (CBE): Annual physical examination of both breasts and axillary lymph nodes performed by trained healthcare providers (ANM / CHO).
   • Red Flags: Hard, painless, solitary, immobile lump with irregular borders; unilateral spontaneous bloody or serosanguinous nipple discharge; nipple retraction or inversion; localized skin dimpling or orange peel appearance (peau d'orange); and palpable ipsilateral axillary lymphadenopathy.
   • Client Education: Instruct all adult women on monthly Breast Self-Examination (BSE), ideally conducted 7 to 10 days after the onset of the menstrual cycle, when breast tissue is least engorged and tender.
5. Cervical Cancer Screening (Visual Inspection with Acetic Acid - VIA):
   • Procedure: A bivalve Cusco speculum is inserted to expose the cervix. Freshly prepared 3% to 5% dilute acetic acid is applied to the cervix using a sterile cotton swab.
   • Observation: The transformation zone and squamo-columnar junction (SCJ) are inspected under a halogen examination lamp after waiting 1 full minute.
   • Positive VIA Test: Appearance of a distinct, well-demarcated, opaque, dense acetowhite lesion with sharp margins touching or abutting the squamo-columnar junction. Occurs because dysplastic neoplastic cells contain increased nuclear proteins that reversibly coagulate upon exposure to acetic acid. Positive women are referred immediately for colposcopy and directed biopsy.

4. Master Reference Tables: Anti-TB Drugs & Vector-Borne Diseases

First-Line Anti-Tuberculosis Drugs & Clinical Nursing Considerations

High-Yield Comparison of Major Vector-Borne Diseases in India